Inhaled Fentanyl Citrate & Dyspnea
Dyspnea
About this trial
This is an interventional treatment trial for Dyspnea focused on measuring Fentanyl Citrate, Opioids, Exercise
Eligibility Criteria
Inclusion Criteria:
- Male
- Aged 20-40 years
- FEV1 ≥80% predicted
- FEV1/FVC >70%
Exclusion Criteria:
- Current or ex-smoker
- Body Mass Index <18.5 or >30 kg/m2
- History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
- Taking doctor prescribed medications
- History of using pain-relieving (opioid) and/or anti-depressant medications in the previous 6 weeks
- Allergy to latex
- Allergy to lidocaine or its "caine" derivatives
Sites / Locations
- Montreal Chest Institute; McGill University Health Center & McGill University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Active Comparator
Placebo Comparator
CWS+Fentanyl Citrate (250 mcg)
CWS+0.9% saline placebo
No CWS+Fentanyl Citrate (250 mcg)
No CWS+0.9% saline placebo
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo